Ranolazine is indicated for the treatment of angina pectoris in patients who have not responded satisfactorily to other antianginals and should be given as an adjunct to standard therapy.
Each extended release tablet contains:
Ranolazine is contraindicated in patients with:
Hypersensitivity to the active substance or to any of the excipients
Severe renal impairment (creatinine clearance < 30 mL/min).
Moderate or sever heptic impairment
Concormitant administration of potent CYP3A4 inhibators (e.g. itraconazole, ketoconazole, voriconazole, posaconazole, HIV protese inhibitors, clarithromycin, telithromycin, nefazodone)
Concomitant administration of Class (e.g. quindine) or Class III (e.g. dofetilide sotalol) antiarrhythmics other than amiodarone.
Dosage and Administration
Initiate Ranolazine dosing at 500mg twice daily and increase to 1 g twice daily, as needed, based on clinical symptoms. Take Ranolazine with or without meals. Swallow Ranolazine tablets whole; do not crush, break, or chew. The maximum recommended daily dose of Ranozaline is 1 g twice daily. If a dose of Ranozaline is missed, take the prescribed dose at the next scheduled time; do not double the next dose.
Dose adjustments may be needed when Ranolazine is taken in combination with certain other drugs. Limit the maximum dose of Ranolazine to 500 mg twice daily in patients on diltiazem, verapamil, and other moderate CYP3A inhibitors. Down-titrate Ranolazine based on clinical response in patients concomitantly treated with P-gp inhibitors, such as ciclosporin.